Literature DB >> 33446610

R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models.

Charifa Awada1, Yann Grobs1, Wen-Hui Wu1,2, Karima Habbout1, Charlotte Romanet1, Sandra Breuils-Bonnet1, Eve Tremblay1, Sandra Martineau1, Roxane Paulin1,3, Sébastien Bonnet1,3, Steeve Provencher1,3, François Potus1,3,4, Olivier Boucherat5,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33446610     DOI： 10.1183/13993003.03271-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  4 in total

Review 1.  The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.

Authors:  Olivier Boucherat; Vineet Agrawal; Allan Lawrie; Sebastien Bonnet
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

2.  Crizotinib for ROS1-rearranged lung cancer and pulmonary tumor thrombotic microangiopathy under venoarterial extracorporeal membrane oxygenation.

Authors:  Daisetsu Aoyama; Shigefumi Fukui; Haruhiko Hirata; Keiko Ohta-Ogo; Hideo Matama; Emi Tateishi; Tatsuya Nishii; Yasuhide Asaumi; Mamoru Toyofuku; Tatsuyoshi Ikeue; Takeshi Ogo; Hatsue Ishibashi-Ueda; Satoshi Yasuda
Journal:  Pulm Circ       Date:  2022-02-21       Impact factor: 2.886

Review 3.  Differentiating pulmonary hypertension associated with protein kinase inhibitors.

Authors:  Joshua A Jacobs; Eiman Jahangir; John J Ryan
Journal:  Pulm Circ       Date:  2022-05-11       Impact factor: 2.886

Review 4.  Metabolic reprogramming: A novel metabolic model for pulmonary hypertension.

Authors:  Xuhan Liu; Liping Zhang; Weihua Zhang
Journal:  Front Cardiovasc Med       Date:  2022-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.